Key result
Cancer therapies, particularly anthracyclines, are associated with significant dose-dependent cardiotoxicity, highlighting an unmet need for safe cardioprotective strategies and long-term surveillance.
This review emphasizes the increasing incidence of cancer therapy-induced cardiovascular diseases and the critical need for long-term surveillance and novel cardioprotective drugs.
Authors
No takes yet. Share an insight, caveat, or question.
May warrant enhanced surveillance during anthracycline therapy; leaves open optimal cardioprotective strategies for prospective validation.
Pierre A. Guertin (2017) conducted a review in Cancer Therapy-Induced Cardiotoxicity. Cancer therapies (e.g., anthracyclines) was evaluated. Cancer therapies, particularly anthracyclines, are associated with significant dose-dependent cardiotoxicity, highlighting an unmet need for safe cardioprotective strategies and long-term surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: